文献速递核素与放射性配体治疗肿瘤 PET/CT

基线临床特征可预测接受[177Lu]Lu-PSMA I&T放射配体治疗患者的长期随访总生存期

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-06-02

该回顾性研究纳入92例接受[177Lu]Lu-PSMA I&T放射配体治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,随访至少18个月,采用多变量Cox回归分析基线临床特征与总生存期(OS)的关系。基线C反应蛋白(CRP)、乳酸脱氢酶(LDH)、天冬氨酸氨基转移酶(AST)及从初诊到首次RLT的间隔时间被确定为OS的独立预后因素。作者认为这些基线特征可能帮助核医学专科医生识别长期生存者。

要点

  • 基线CRP、LDH、AST升高及初诊至RLT间隔较短与mCRPC患者接受[177Lu]Lu-PSMA I&T后OS缩短独立相关。
  • ROC确定的阈值:CRP 0.98 mg/dl、LDH 276.5 U/l、AST 26.95 U/l、间隔43.5个月。
  • 作者认为这些基线特征可能帮助识别长期生存者。

核心结论

  • 在mCRPC患者中,基线CRP、LDH、AST及至RLT启动的时间间隔(可能反映肿瘤侵袭性)与生存独立相关。
  • 作者认为这些临床基线特征可能帮助核医学专科医生识别长期生存者。

研究设计与样本

  • 回顾性识别92例接受[177Lu]Lu-PSMA I&T治疗且随访至少18个月的mCRPC患者。
  • 对多种基线特征(包括实验室值、Gleason评分、年龄、既往治疗及初诊至首次治疗周期间隔)进行多变量Cox回归分析。
  • 使用ROC分析确定显著预测因素的截断值,并将ROC得出的阈值应用于Kaplan-Meier分析。

主要发现

  • 基线CRP(HR 1.10,95%CI 1.02-1.18;P=0.01)、LDH(HR 1.07,95%CI 1.01-1.11;P=0.01)、AST(HR 1.16,95%CI 1.06-1.26;P=0.001)及intervalDiagnosis-RLT(每12个月,HR 0.95,95%CI 0.91-0.99;P=0.02)为OS的独立预后因素。
  • ROC阈值:CRP 0.98 mg/dl(AUC 0.80);LDH 276.5 U/l(AUC 0.83);AST 26.95 U/l(AUC 0.73);intervalDiagnosis-RLT 43.5个月(AUC 0.68;P<0.01)。
  • Kaplan-Meier分析显示,CRP较低、LDH较低、AST较低以及intervalDiagnosis-RLT较长的患者中位OS显著更长(P≤0.01)。

关键数值与推荐

  • 基线CRP每升高1单位,OS的HR为1.10(95%CI 1.02-1.18;P=0.01)。
  • 基线LDH每升高1单位,OS的HR为1.07(95%CI 1.01-1.11;P=0.01)。
  • 基线AST每升高1单位,OS的HR为1.16(95%CI 1.06-1.26;P=0.001)。
  • intervalDiagnosis-RLT每增加12个月,OS的HR为0.95(95%CI 0.91-0.99;P=0.02)。
  • ROC阈值:CRP 0.98 mg/dl(AUC 0.80);LDH 276.5 U/l(AUC 0.83);AST 26.95 U/l(AUC 0.73);intervalDiagnosis-RLT 43.5个月(AUC 0.68;P<0.01)。

临床怎么用

  • 作者认为基线CRP、LDH、AST及至RLT启动的时间间隔可能支持核医学专科医生识别长期生存者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioligand therapy (RLT) with 177Lu-labeled prostate-specific membrane antigen (PSMA) ligands is associated with prolonged overall survival (OS) in patients with advanced, metastatic castration-resistant prostate cancer (mCRPC). A substantial number of patients, however, are prone to treatment failure. We aimed to determine clinical baseline characteristics to predict OS in patients receiving [177Lu]Lu-PSMA I&T RLT in a long-term follow-up. MATERIALS AND METHODS: Ninety-two mCRPC patients treated with [177Lu]Lu-PSMA I&T with a follow-up of at least 18 months were retrospectively identified. Multivariable Cox regression analyses were performed for various baseline characteristics, including laboratory values, Gleason score, age, prior therapies, and time interval between initial diagnosis and first treatment cycle (intervalDiagnosis-RLT, per 12 months). Cutoff values for significant predictors were determined using receiver operating characteristic (ROC) analysis. ROC-derived thresholds were then applied to Kaplan-Meier analyses. RESULTS: Baseline C-reactive protein (CRP; hazard ratio [HR], 1.10, 95% CI 1.02-1.18; P = 0.01), lactate dehydrogenase (LDH; HR, 1.07, 95% CI 1.01-1.11; P = 0.01), aspartate aminotransferase (AST; HR, 1.16, 95% CI 1.06-1.26; P = 0.001), and intervalDiagnosis-RLT (HR, 0.95, 95% CI 0.91-0.99; P = 0.02) were identified as independent prognostic factors for OS. The following respective ROC-based thresholds were determined: CRP, 0.98 mg/dl (area under the curve [AUC], 0.80); LDH, 276.5 U/l (AUC, 0.83); AST, 26.95 U/l (AUC, 0.73); and intervalDiagnosis-RLT, 43.5 months (AUC, 0.68; P < 0.01, respectively). Respective Kaplan-Meier analyses demonstrated a significantly longer median OS of patients with lower CRP, lower LDH, and lower AST, as well as prolonged intervalDiagnosis-RLT (P ≤ 0.01, respectively). CONCLUSION: In mCRPC patients treated with [177Lu]Lu-PSMA I&T, baseline CRP, LDH, AST, and time interval until RLT initiation (thereby reflecting a possible indicator for tumor aggressiveness) are independently associated with survival. Our findings are in line with previous findings on [177Lu]Lu-PSMA-617, and we believe that these clinical baseline characteristics may support the nuclear medicine specialist to identify long-term survivors.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hartrampf PE, Seitz AK, Weinzierl FX, et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022. PMID: 35650263. doi:10.1007/s00259-022-05853-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。